Fair-Value Report — Xunfei Healthcare Technology (2506.HK)

Insider Signal

Verified Snapshot

FX: 1 CNY = HKD 1.1549 (Wise mid-market, 8 Jun 2026). All financial figures in CNY (company's reporting currency) unless stated otherwise. Market cap and per-share prices in HKD.

Business Overview

Xunfei Healthcare Technology (訊飛醫療科技股份有限公司) is China's leading healthcare AI company, listed on HKEX in December 2024. It is approximately 72–73% owned by iFlytek Co., Ltd. (科大訊飛, SSE: 002230), China's dominant speech and AI technology group. Xunfei Healthcare provides AI-powered clinical decision support, smart hospital infrastructure, and primary care AI tools to hospitals, clinics, and government health bureaus across the PRC.

Four Business Segments

Market Position (2023 data, per prospectus)

• #1 in China's overall medical AI market by revenue (5.9% share)
• #1 in China's primary care CDSS market (61.5% market share)
• #5 in hospital CDSS market (4.7% share)

In 2025 the company won a national AI application pilot contract worth CNY 428M covering intelligent diagnostics, public health, and chronic disease management — cementing its role as China's AI healthcare infrastructure provider. Revenue has grown from CNY 556M (FY2023) → CNY 734M (FY2024) → CNY 915M (FY2025), a 28% 2-year CAGR, while the net loss has narrowed sharply each year (from CNY -189M in FY2022 to CNY -65M in FY2025).

Financial History

Sources: stockanalysis.com (cross-checked against etnet.com.hk, Sina Finance, AAStocks). FY2025 annual results published 27 Mar 2026. H1 2025 interim: revenue CNY 299M (+30% YoY), gross margin 51.5%.

Valuation

Method: Revenue Multiple (P/S) + P/B Floor

Xunfei Healthcare is a loss-making, high-growth technology company with no near-term free cash flow. A DCF is not applicable. The appropriate primary method is Price-to-Sales (P/S) relative to a forward revenue estimate, anchored against listed peers in the Chinese healthcare digital / AI space. P/B serves as a secondary floor check.

Reverse read at current price (HKD 80.55): The market capitalisation of HKD 9.74B implies 9.2× FY2025 revenue (HKD ~1.06B equivalent). For a company growing at 25% with a 50% gross margin and a loss that is halving each year, this multiple is premium relative to profitable digital-health peers (JD Health ~2–3× P/S, Alibaba Health ~2–3×, Ping An Good Doctor ~3–5×). The premium is paid for: (a) China's dominant primary care AI position with 61.5% CDSS market share, (b) the asset-light software model at scale, and (c) clear path to breakeven by FY2027E. The question is whether 9× is the right price for that premium before profitability is proven.

Scenario Table (12-Month Fair Value)

Fair value estimate: HKD 87 (probability-weighted mid-point). At HKD 80.55, the stock trades at an ~8% discount to base-case fair value, with a 53% bull-case scenario backed by a high-conviction insider accumulation signal. The parent's willingness to deploy HKD ~88.6M into the open market at near-IPO prices over two weeks is the most significant data point — they have full operational visibility and chose to buy.

P/B Floor Check

Book value per share is CNY 7.42 = HKD 8.57. At HKD 80.55, the stock trades at 9.4× P/B. This is a high multiple for a loss-making company and confirms valuation is entirely growth-driven. There is no meaningful asset-value support at current prices; the P/B floor is far below.

Peer Comparison

2506.HK commands a significant P/S premium over profitable peers. This is warranted only if (a) 25%+ revenue growth is sustained and (b) the company reaches operating breakeven within 2 years. The CNY 428M national contract win and consistent loss-narrowing trend support this thesis. No true pure-play listed peer exists in this exact niche.

Conclusion

Rating: SPECULATIVE BUY — Fair value HKD 87, current price HKD 80.55 (8 Jun 2026).

The insider signal is high quality: iFlytek, the fully-informed parent company, committed HKD ~88.6M to open-market purchases over two weeks at near-IPO prices. This is a meaningful vote of confidence from the entity with the deepest operational insight into H1 2026 performance (not yet public). The business fundamentals support the signal: revenue growing 25%, net losses halving YoY, #1 position in China's primary care AI market, and a CNY 428M national contract providing revenue visibility.

However, investors must be clear-eyed about the risks. The cash position is tight (CNY 124M vs CNY 283M debt), the valuation premium to profitable peers is high (9.2× P/S), and the lock-up on 72.86% of shares expires December 2026 — creating a supply overhang in six months. The float is thin (~27%), making the stock volatile and illiquid. The gross margin has also compressed from 55% to 50% over two years, which merits monitoring.

The asymmetric opportunity: if Xunfei Healthcare achieves near-breakeven by H2 2026 (plausible given loss trajectory), the stock could re-rate significantly toward the bull case (HKD 123). The bear case (HKD 46) implies a dilutive fundraise and major de-rating — possible if cash continues to drain without a corresponding revenue acceleration. Given the insider's conviction at these prices, the base/bull probability exceeds 50%. Appropriate position sizing: small; treat as a monitored speculative position pending H1 2026 interim results (expected ~August 2026).

Key Risks

• Cash depletion / dilution risk: Cash collapsed from CNY 677M to CNY 124M in FY2025; if this trajectory continues without revenue acceleration, a dilutive equity raise is plausible within 12–18 months.
• Lock-up expiry (December 2026): 88.1M shares (72.86% of float) become tradeable at year-end 2026. iFlytek and other major pre-IPO holders may partially reduce holdings, creating significant supply.
• Thin float / illiquidity: Only ~27% of shares freely tradeable; small trades can move the price materially. Average daily volume is low.
• Government procurement concentration: Revenue is heavily weighted toward public-sector contracts in China. Procurement delays, budget reallocations, or policy shifts can create lumpy, unpredictable revenue.
• Gross margin compression: Gross margin has trended down from 56.6% (FY2023) to 50.4% (FY2025). Further compression would delay breakeven.
• Big-tech competition: Alibaba Health, Tencent, and Baidu are all investing in healthcare AI. iFlytek's technology moat in speech/AI is an advantage, but not a permanent barrier.
• China regulatory and geopolitical risk: A China-listed company with H-shares; subject to PRC regulatory changes, data localisation requirements, and HK-China market sentiment.
• H1 2026 data gap: Interim results not expected until ~August 2026. Cash and loss position as of June 2026 are unknown.

Sources

• HKEX Disclosure of Interests filings — stock code 2506 (via Eastmoney Guba, Sina Finance aggregators; direct portal temporarily unavailable at research time)
• stockanalysis.com — 2506.HK income statement, balance sheet, key stats (cross-checked 8 Jun 2026)
• etnet.com.hk — FY2025 EPS (CNY -0.540), book value (CNY 7.417)
• AAStocks / 智通財經 — H1 2025 interim results (revenue CNY 298.6M, gross margin 51.5%)
• HKEX FY2025 Annual Results Announcement (published 27 Mar 2026): hkexnews.hk/listedco/listconews/sehk/2026/0327/[CARD].pdf
• Sina Finance, Gelonghui, Eastmoney — purchase disclosures and corporate news
• Investing.com / Hstong / Webull — price data (8 Jun 2026)
• Wise — CNY/HKD rate: 1 CNY = 1.1549 HKD (8 Jun 2026)
• Sohu Finance — Lock-up extension announcement (Dec 2025)
• CMBI Research — 2506.HK initiation report (Mar 2025)